Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:56 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 3,756 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 2 Interventional Results available

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

NCT03643510
View directory record Official record
Conditions
Adenocarcinoma of Endometrium
Interventions
Fulvestrant, Abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Completed Not applicable Interventional Results available

Chiropractic for Hypertension in Patients

NCT01020435
View directory record Official record
Conditions
Hypertension
Interventions
Spinal Manipulation, Sham Spinal Manipulation
Other
Lead sponsor
Palmer College of Chiropractic
Other
Eligibility
21 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Nov 3, 2026, 2:56 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Curcumin for the Chemoprevention of Colorectal Cancer

NCT00118989
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
Curcuminoids
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

NCT00468169
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 3 Interventional Results available

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

NCT01655069
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin succinate suspension
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254
View directory record Official record
Conditions
Herpes Simplex
Interventions
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Treatment With Pazopanib for Neoadjuvant Breast Cancer

NCT00849472
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery, pazopanib monotherapy
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
137
States / cities
Decatur, Alabama • Huntsville, Alabama • Antioch, California + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1 Interventional Results available

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

NCT03602612
View directory record Official record
Conditions
Myeloma-Multiple, Myeloma, Plasma-Cell
Interventions
Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1 Interventional

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Nov 3, 2026, 2:56 PM EST
Completed No phase listed Observational Results available

Utility of Novel BRAF Test for Melanoma

NCT01840527
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Not yet recruiting Phase 2 Interventional

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

NCT07502872
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Interventions
Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Terminated Phase 1Phase 2 Interventional Results available

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

NCT00686842
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 3 Interventional Results available

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

NCT01721746
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
BMS-936558, Dacarbazine, Carboplatin, Paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
32
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Nov 3, 2026, 2:56 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NCT00439569
View directory record Official record
Conditions
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
Westat
Other
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Stanford, California • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1 Interventional

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01134341
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Nov 3, 2026, 2:56 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Pancreatic Cancer Early Detection Consortium

NCT04970056
View directory record Official record
Conditions
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years to 90 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

NCT00422656
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Nov 3, 2026, 2:56 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study

NCT07596888
View directory record Official record
Conditions
HIV-1-infection
Interventions
IAP086 0.3 mcg/kg, IAP086 1 mcg/kg, IAP086 3 mcg/kg, IAP086 6 mcg/kg, IAP086 10 mcg/kg, IAP086 15 mcg/kg, IAP086 25 mcg/kg, IAP086 32 mcg/kg, IAP086 40 mcg/kg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 2:56 PM EST
Terminated Phase 2 Interventional Results available

Topical Raplixa for Surgical Bleeding in Children

NCT02117349
View directory record Official record
Conditions
Surgical Bleeding
Interventions
Raplixa, Gelfoam, Rescue treatment
Drug · Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
Up to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
View directory record Official record
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 3 Interventional Results available

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

NCT00358501
View directory record Official record
Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
22
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1 Interventional Results available

Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

NCT01777412
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Bevacizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Nov 3, 2026, 2:56 PM EST
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 3, 2026, 2:56 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 3, 2026, 2:56 PM EST